他汀类药物的使用与2型糖尿病患者动脉粥样硬化性心血管疾病一级预防中低密度脂蛋白胆固醇目标的达成:斯里兰卡的一项多中心横断面研究

Statin use and low-density lipoprotein cholesterol target achievement for primary prevention of atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus: a multicenter cross-sectional study in Sri Lanka.

作者信息

De Zoysa P D W D, Weerarathna T P, Darshana I L A N, Wasana K G P, Piyasekara B, Jayasekara M M P T, Sujanitha V, Silva S, Mettananda C, Ramadasa G U, Pathirage L P M M K

机构信息

Faculty of Medicine, University of Ruhuna, Sri Lanka.

Faculty of Health Sciences, CINEC Campus, Sri Lanka.

出版信息

PLoS One. 2025 Feb 21;20(2):e0319030. doi: 10.1371/journal.pone.0319030. eCollection 2025.

Abstract

BACKGROUND

Statin therapy serves a crucial role as a primary preventive strategy against atherosclerotic cardiovascular disease (ASCVD) in patients with type 2 diabetes mellitus (T2DM). Even though diabetes poses a significant and growing health concern in Sri Lanka, there is a lack of information regarding the prevalence and intensity of statin prescriptions and the achievement of recommended LDL-C targets in diabetic patients for the primary prevention of ASCVD within the nation. We aimed to assess the prevalence and intensity of statin prescriptions, target LDL-C achievement, and factors associated with target LDL-C achievement for the primary prevention of ASCVD in T2DM patients across several tertiary care facilities in Sri Lanka.

METHODS

A multi-centered, cross-sectional study was conducted among T2DM patients without clinical ASCVD attending six tertiary care medical clinics in Sri Lanka. Data on ASCVD risk factors and statin prescription were collected using an interviewer-administered questionnaire. ASCVD risk was calculated using the WHO charts. Atorvastatin 20 mg/ rosuvastatin 10 mg was defined as high-intensity statins and target LDL-C was defined as < 70 mg/dL for moderate to high and < 100 mg/dL for low-risk groups of ASCVD according to the NICE guideline. The independent sample t test, one-way ANOVA and chi-square test were used for data analysis as appropriate. Factors linked to achieving LDL-C targets were determined through multiple logistic regression analysis. Level of significance was considered as 0.05.

RESULTS

Of the 2013 participants studied, 46.7% were at moderate-high risk and the rest were at low risk of ASCVD. All were eligible for statin therapy, and 84.1% were prescribed statins. High-intensity statins had been prescribed only for 38.5% of moderate-high-risk patients. Nonetheless, high-intensity statins have also been prescribed for 30.7% of low-risk patients. LDL-C target achievement was studied in a randomly selected subsample of 683 and 65.4% (70.7% in low-risk patients and 60.3% in moderate-high-risk patients) achieved LDL-C targets. Of moderate-high-risk patients, 46.3% had not achieved target LDL-C even with high-intensity statin therapy. Female gender (OR = 1.52, 95% CI 1.03-2.24, p = 0.036), poor adherence to statins (OR = 1.67, 95% CI 1.18-2.37, p = 0.004), poor glycemic control (OR = 2.27, 95% CI 1.41-3.65, p = 0.001), and inadequate physical activity (OR = 1.48, 95% CI 1.04-2.10, p = 0.031) were significantly associated with failing to achieve LDL-C targets.

CONCLUSION

Only about one third of diabetes patients with moderate-high ASCVD risk received high-intensity statins. Even with high-intensity statin therapy, nearly half of the treated patients failed to meet recommended LDL-C targets.

摘要

背景

他汀类药物治疗在2型糖尿病(T2DM)患者预防动脉粥样硬化性心血管疾病(ASCVD)的一级预防策略中起着关键作用。尽管糖尿病在斯里兰卡是一个重大且日益严重的健康问题,但该国缺乏关于糖尿病患者他汀类药物处方的患病率和强度以及实现推荐的低密度脂蛋白胆固醇(LDL-C)目标以进行ASCVD一级预防的相关信息。我们旨在评估斯里兰卡几家三级医疗设施中T2DM患者预防ASCVD的他汀类药物处方的患病率和强度、LDL-C目标达成情况以及与LDL-C目标达成相关的因素。

方法

对斯里兰卡六家三级医疗诊所中无临床ASCVD的T2DM患者进行了一项多中心横断面研究。使用访谈式问卷收集ASCVD危险因素和他汀类药物处方的数据。使用世界卫生组织图表计算ASCVD风险。根据英国国家卫生与临床优化研究所(NICE)指南,阿托伐他汀20毫克/瑞舒伐他汀10毫克被定义为高强度他汀类药物,对于ASCVD中高风险组,目标LDL-C定义为<70毫克/分升,对于低风险组定义为<100毫克/分升。根据情况使用独立样本t检验、单因素方差分析和卡方检验进行数据分析。通过多因素逻辑回归分析确定与实现LDL-C目标相关的因素。显著性水平设定为0.05。

结果

在研究的2013名参与者中,46.7%处于中高风险,其余处于ASCVD低风险。所有患者均符合他汀类药物治疗条件,84.1%的患者开具了他汀类药物。仅38.5%的中高风险患者开具了高强度他汀类药物。然而,30.7%的低风险患者也开具了高强度他汀类药物。在随机抽取的683名子样本中研究了LDL-C目标达成情况,65.4%(低风险患者中为70.7%,中高风险患者中为60.3%)实现了LDL-C目标。在中高风险患者中,即使接受高强度他汀类药物治疗,仍有46.3%未达到LDL-C目标。女性(比值比[OR]=1.52,95%置信区间[CI] 1.03 - 2.24,p = 0.036)、对他汀类药物依从性差(OR = 1.67,95% CI 1.18 - 2.37,p = 0.004)、血糖控制不佳(OR = 2.27,95% CI 1.41 - 3.65,p = 0.001)以及体力活动不足(OR = 1.48,95% CI 1.04 - 2.10,p = 0.031)与未实现LDL-C目标显著相关。

结论

只有约三分之一的ASCVD中高风险糖尿病患者接受了高强度他汀类药物治疗。即使接受高强度他汀类药物治疗,近一半的治疗患者仍未达到推荐的LDL-C目标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f94e/11844856/a7d76e78272f/pone.0319030.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索